[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2014MN02418A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02418A
IN2014MN02418A IN2418MUN2014A IN2014MN02418A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A IN 2418MUN2014 A IN2418MUN2014 A IN 2418MUN2014A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A
Authority
IN
India
Prior art keywords
methods
breast cancer
subject
gene expression
evaluating
Prior art date
Application number
Inventor
Sean M Ferree
James Justin Storhoff
Joel S Parker
Charles M Perou
Matthew J Ellis
Philip S Bernard
Torsten O Nielsen
Original Assignee
Nanostring Technologies Inc
Univ North Carolina
Univ Utah Res Found
British Columbia Cancer Agency
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc, Univ North Carolina, Univ Utah Res Found, British Columbia Cancer Agency, Univ Washington filed Critical Nanostring Technologies Inc
Publication of IN2014MN02418A publication Critical patent/IN2014MN02418A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles including microarrays and quantitative polymerase chain reaction assays as well as kits comprising reagents for practicing the methods of the invention.
IN2418MUN2014 2012-05-22 2013-05-22 IN2014MN02418A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US201361753673P 2013-01-17 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (1)

Publication Number Publication Date
IN2014MN02418A true IN2014MN02418A (en) 2015-08-14

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2418MUN2014 IN2014MN02418A (en) 2012-05-22 2013-05-22

Country Status (12)

Country Link
US (3) US20130337444A1 (en)
EP (1) EP2852689B1 (en)
JP (1) JP6325530B2 (en)
CN (2) CN104704128A (en)
AU (1) AU2013266419B2 (en)
BR (1) BR112014029300A2 (en)
CA (1) CA2874492C (en)
ES (1) ES2763931T3 (en)
IL (1) IL235795B (en)
IN (1) IN2014MN02418A (en)
MX (1) MX369628B (en)
WO (1) WO2013177245A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2457534T3 (en) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Gene expression profiles to predict outcomes in breast cancer
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
JP6144695B2 (en) 2011-11-30 2017-06-07 ユニバーシティー オブ ノースカロライナ アット チャペル ヒル How to treat breast cancer with taxane therapy
DK3511423T4 (en) 2012-10-17 2024-07-29 Spatial Transcriptomics Ab METHODS AND PRODUCT FOR OPTIMIZING LOCALIZED OR SPATIAL DETECTION OF GENE EXPRESSION IN A TISSUE SAMPLE
WO2014186349A1 (en) * 2013-05-13 2014-11-20 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
CA2916660C (en) 2013-06-25 2022-05-17 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
AU2014317843A1 (en) 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
EP4029952A1 (en) 2014-11-21 2022-07-20 Nanostring Technologies, Inc Enzyme- and amplification-free sequencing
EP3223947B1 (en) * 2014-11-24 2019-10-30 Nanostring Technologies, Inc. Methods and apparatuses for gene purification and imaging
WO2016091880A1 (en) * 2014-12-09 2016-06-16 King's College London Breast cancer treatment with taxane therapy
JP6828007B2 (en) 2015-04-10 2021-02-10 スペーシャル トランスクリプトミクス アクチボラグ Spatial-identified multiplex nucleic acid analysis of biological samples
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
EP4324929A1 (en) 2016-05-16 2024-02-21 Nanostring Technologies, Inc. Methods for detecting target nucleic acids in a sample
EP3472359B1 (en) 2016-06-21 2022-03-16 10X Genomics, Inc. Nucleic acid sequencing
WO2018074865A2 (en) * 2016-10-21 2018-04-26 서울대학교병원 Composition and method for breast cancer prognosis prediction
JP6730525B2 (en) 2016-11-21 2020-07-29 ナノストリング テクノロジーズ,インコーポレイティド Chemical composition and method of using the same
KR101950717B1 (en) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 Methods for predicting effectiveness of chemotherapy for breast cancer patients
US11978535B2 (en) * 2017-02-01 2024-05-07 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
CN111263819A (en) 2017-10-06 2020-06-09 卡特阿纳公司 RNA templated ligation
KR102071491B1 (en) * 2017-11-10 2020-01-30 주식회사 디시젠 Breast cancer prognosis prediction method and system based on machine learning using next generation sequencing
SG11202011274YA (en) 2018-05-14 2020-12-30 Nanostring Technologies Inc Chemical compositions and methods of using same
CN113302313A (en) * 2018-11-05 2021-08-24 拜恩科技诊断有限责任公司 Method for predicting breast cancer
EP3976817A1 (en) 2019-05-31 2022-04-06 10X Genomics, Inc. Method of detecting target nucleic acid molecules
JP7352937B2 (en) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 Differential marker gene set, method and kit for differentiating or classifying breast cancer subtypes
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
US12060603B2 (en) 2021-01-19 2024-08-13 10X Genomics, Inc. Methods for internally controlled in situ assays using padlock probes
WO2023117807A1 (en) * 2021-12-20 2023-06-29 Reveal Genomics S.L Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN117965734B (en) * 2024-02-02 2024-09-24 奥明星程(杭州)生物科技有限公司 Gene marker for detecting hard fibroid, kit, detection method and application

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69217497T2 (en) 1991-09-18 1997-06-12 Affymax Tech Nv METHOD FOR SYNTHESISING THE DIFFERENT COLLECTIONS OF OLIGOMERS
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
JP4680898B2 (en) * 2003-06-24 2011-05-11 ジェノミック ヘルス, インコーポレイテッド Predicting the likelihood of cancer recurrence
US20050071087A1 (en) * 2003-09-29 2005-03-31 Anderson Glenda G. Systems and methods for detecting biological features
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101061480A (en) * 2004-09-22 2007-10-24 三路影像公司 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
ATE525482T1 (en) 2005-12-23 2011-10-15 Nanostring Technologies Inc NANOREPORTERS AND METHOD FOR THE PRODUCTION AND USE THEREOF
ES2402939T3 (en) 2005-12-23 2013-05-10 Nanostring Technologies, Inc. Compositions comprising immobilized and oriented macromolecules and methods for their preparation
AU2008237018B2 (en) 2007-04-10 2014-04-03 Bruker Spatial Biology, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
CA2698569A1 (en) * 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
ES2457534T3 (en) * 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Gene expression profiles to predict outcomes in breast cancer
EP2331704B1 (en) 2008-08-14 2016-11-30 Nanostring Technologies, Inc Stable nanoreporters
UA110790C2 (en) * 2010-03-31 2016-02-25 Сівідон Діагностікс Гмбх Method for breast cancer recurrence prediction under endocrine treatment

Also Published As

Publication number Publication date
CN104704128A (en) 2015-06-10
EP2852689A4 (en) 2016-05-11
AU2013266419B2 (en) 2018-09-27
MX369628B (en) 2019-11-14
EP2852689B1 (en) 2019-12-11
EP2852689A2 (en) 2015-04-01
CA2874492A1 (en) 2013-11-28
CN111500718A (en) 2020-08-07
IL235795B (en) 2020-02-27
CA2874492C (en) 2021-10-19
AU2013266419A1 (en) 2014-12-11
US20230272476A1 (en) 2023-08-31
US20130337444A1 (en) 2013-12-19
US20200332368A1 (en) 2020-10-22
JP2015518724A (en) 2015-07-06
ES2763931T3 (en) 2020-06-01
JP6325530B2 (en) 2018-05-16
BR112014029300A2 (en) 2017-07-25
IL235795A0 (en) 2015-01-29
WO2013177245A2 (en) 2013-11-28
WO2013177245A3 (en) 2015-01-29
MX2014014275A (en) 2015-07-06

Similar Documents

Publication Publication Date Title
IN2014MN02418A (en)
CY1114993T1 (en) Gene Expression Profile To Predict Breast Cancer Outcomes
EA201390762A1 (en) NEW BIOMARKERS TO PREDICT THE OUTCOME OF ANTICATIVE IMMUNOTHERAPY
MX2019007814A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
MX2020001156A (en) Method for the prognosis and treatment of cancer metastasis.
NZ599194A (en) Methods to predict clinical outcome of cancer
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
MX2019000091A (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer.
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
CY1117838T1 (en) PREDICTION FACTORS FOR CANCER TREATMENT
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
BR112015022977A2 (en) methods for predicting risk of metastasis in cutaneous melanoma
MX2016012718A (en) Determination of single nucleotide polymorphisms useful to predict response for rasagiline.
RU2010149541A (en) METHOD FOR FORECASTING THE DEVELOPMENT OF METABOLIC SYNDROME IN A PATIENT WITH ABDOMINAL OBESITY
Eapen Relapsed acute lymphoblastic leukemia: Is it crucial to achieve molecular remission prior to transplant?
MX2017004816A (en) Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis.
RU2012142904A (en) METHOD FOR PREDICING RISK OF PSORIASIS AND PSORIATIC ARTHRITIS DEVELOPMENT
Tong-xia et al. A 1: 2 Case-control Study of Tap2/HLA-DR9 Gene Polymorphism with Esophageal Cancer in Kazakh
UA108260U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
UA95616U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
Brennan Quantifying Biomarker Risks and Benefits